Balyasny Asset Management »

Summit Therapeutics shares owned by Balyasny Asset Management

Quarter-by-quarter ownership of Summit Therapeutics (SMMT) shares owned by Balyasny Asset Management from 13F filings

Historical chart of Balyasny Asset Management investment in Summit Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Summit Therapeutics held by Balyasny Asset Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Summit Therapeutics by Balyasny Asset Management

Quarter filed Position value Share count Share price at filing
2024-06-30 $7.9M 1.0M 7.80
2023-06-30 $26k 10k 2.51
2023-03-31 $62k 36k 1.75

More positions owned by Balyasny Asset Management

Ishares Tr Russell 2000 Etf (IWM)
Apple Call Option (AAPL)
Invesco Qqq Tr Unit Ser 1 (QQQ)
Spdr S&p 500 Etf Tr Tr Unit Call Option (SPY)
Select Sector Spdr Tr Financial (XLF)
Microsoft Corporation Call Option (MSFT)
Amazon Call Option (AMZN)
NVIDIA Corporation Call Option (NVDA)
Ishares Tr Core S&p Mcp Etf (IJH)
Vanguard Index Fds Total Stk Mkt (VTI)
Select Sector Spdr Tr Sbi Cons Discr (XLY)
Mastercard Incorporated Cl A Call Option (MA)
Hess Call Option (HES)
Lockheed Martin Corporation Call Option (LMT)
Endeavor Group Hldgs Cl A Com Put Option (EDR)

View all positions for Balyasny Asset Management

Top funds holding Summit Therapeutics

Baker Bros. Advisors
Vanguard Group
BlackRock
BlackRock
T. Rowe Price Associates
State Street Corporation
Geode Capital Management
Jane Street
Susquehanna International
Citadel Advisors
Charles Schwab Investment Management
Standard Life Aberdeen
Darwin Global Management
Balyasny Asset Management
Northern Trust

View all funds holding Summit Therapeutics